MED - Medifast, Inc.
The heavy selling pressure might have exhausted for Medifast (MED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
OPTAVIA's clinical program reduces visceral fat 14% and retains 98% lean mass, directly addressing the metabolic impact of perimenopause and menopause.
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimed DXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scale Study completion rates carry significant weight in how research findings should be interpreted BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically studied," "science-backed," "proven," and "evidence-based" appear across a wide spectrum of programs, from programs with published randomized controlled trials to those with ingredient-level pilot data.
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Here is how Medifast (MED) and New York Times Co. (NYT) have performed compared to their sector so far this year.
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain active.
A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who attempted the program without coaching support (Arterburn LM, et al., 2019) Higher retention in a weight management program is directly correlated with more significant weight loss outcomes, per a 2024 systematic review and meta-analysis OPTAVIA coaches complete a program-specific education curriculum and must pass a certification exam before supporting participants Independent research commissioned by OPTAVIA found that 96% of Americans recognize lifestyle changes are essential for weight loss and management, yet only 17% feel confident they can manage it alone BALTIMORE, MD, May 21, 2026 (GLOBE NEWSWIRE) -- OPTAVIA, a science-backed, coach-guided comprehensive metabolic health system, is built around a core principle: that structured human support changes outcomes.
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research identifying additional counseling and support as key for those showing lower early progress (Coleman CD, et al.
The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the category Randomized controlled trials control for the lifestyle variables and selection bias that self-reported program data cannot account for, making them the standard for evaluating whether a weight loss program itself is driving outcomes Body composition is the breakdown of fat, lean mass, and bone. It shows what weight loss is actually made up of, a distinction that scale weight alone cannot capture A coach can address the specific barriers that may cause program adherence to stall, providing an additional support compared to digital trackers and tools BALTIMORE, MD, May 15, 2026 (GLOBE NEWSWIRE) -- Client experiences and peer-reviewed research are two pillars of evidence that, at their best, reinforce each other.
Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019) Structured plans, habit building, and dedicated coach support work together to produce body composition outcomes that reflect the quality of weight loss, not just its quantity (Arterburn LM, et al.
Medifast trades below net cash value, with $15 per share in cash versus a $12.60 share price, creating a compelling value floor. Coach productivity surged 19% YoY to $5,432 per coach, signaling early signs of operational turnaround despite a shrinking coach base. Cost-cutting initiatives, asset sales, and a positive operating cash flow position MED for potential profitability by Q4 2026, with a $30 million savings target.
Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.50 if the company's earnings stabilize over the mid-term. Such upside is speculative, though.
MED beats first-quarter estimates despite steep revenue declines, while stronger coach productivity and a new product launch support recovery hopes.
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.11 per share a year ago.
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt.
MED reports Q1 fiscal 2026 May 4; revenue seen down 36.3% and EPS at a 55-cent loss as coach base and demand stay pressured.
NEW YORK, April 14, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Medifast, Inc. (NYSE: MED) on behalf of the company's shareholders. The investigation seeks to determine whether Medifast's directors breached their fiduciary duties in connection with recent corporate actions.
MED's science-led metabolic health push and new product pipeline could spark a turnaround as it targets GLP-1 transition users and profitability growth.
Medifast Inc (NYSE: MED - Get Free Report) CEO Daniel Chard acquired 17,678 shares of the stock in a transaction on Friday, March 20th. The stock was bought at an average price of $10.11 per share, with a total value of $178,724.58. Following the transaction, the chief executive officer directly owned 17,678 shares in the company,